10,000+
Orthopedic SKUs & implants under one roof
Medical-Grade Polymer Science
Understanding Acrylic Orthopedic Bone Cement (PMMA) Mechanics
Orthopedic bone cement—primarily composed of Poly(methyl methacrylate) (PMMA)—serves as a vital structural grout in joint arthroplasty, vertebroplasty, and traumatology. Unlike true adhesives, PMMA does not form a chemical bond with human bone tissue. Instead, it functions as a micro-mechanical space-filling buffer that transfers heavy physiological loads evenly from the metallic or ceramic joint implant directly to the surrounding cancellous bone architecture.
For global procurement managers and clinical evaluation committees, selecting the appropriate bone cement involves navigating key rheological properties: dough phase duration, polymerization exotherm, compressive shear strength, radiopacity density, and antibiotic elution kinetics. A failure to match cement viscosity to the specific surgical application (e.g., low viscosity for femoral canal pressurization vs. high viscosity for total knee tibial tray placement) can result in early implant loosening, aseptic failure, or micro-embolization risks.
Product Portfolio
Recommended Orthopedic Bone Cement Formulations for Global Buyers
Sharma Orthopedic manufactures an extensive array of ISO 5833-compliant PMMA acrylic cements designed for specific surgical techniques. Below are our core product lines trusted by orthopedic centers worldwide.
Primary Arthroplasty (TKR / THR)
1. Sharma-Fix High Viscosity PMMA Bone Cement
Clinical Focus: Total Knee Replacement (TKR), Total Shoulder Arthroplasty, and Manual Application Hip Cementing.
Technical Profile: Engineered for immediate manual workability, Sharma-Fix High Viscosity reaches a pliable, non-sticky dough state rapidly (within 60 to 90 seconds post-mixing). It maintains a long, predictable working phase (4 to 6 minutes at 23°C), preventing unbonded surgical laminations during component positioning.
- Radiopacifier: 10% Zirconium Dioxide (ZrO2) or Barium Sulfate (BaSO4) for high intra-operative fluoroscopic clarity.
- Compressive Strength: Exceeds 85 MPa, well above ISO 5833 minimum threshold (70 MPa).
- Packaging: Double-sterile blister pack with 40g powder monomer and 20ml liquid monomer ampoule.
Syringe / Pressure Injection
2. Sharma-Fix Low & Medium Viscosity Bone Cement
Clinical Focus: Femoral Canal Injection in Total Hip Replacement (THR) and Retrograde Cementing Techniques.
Technical Profile: Characterized by an extended low-viscosity liquid phase, this formulation is optimized for syringe delivery systems and vacuum mixing devices. It penetrates deep into the intertrabecular spaces of cancellous bone, creating an optimal micro-interlocking cement-bone interface while lowering air-entrapment porosity.
- Flow Properties: Remains highly fluid for 2.5 to 4 minutes, allowing effortless passage through narrow injection nozzles.
- Polymerization Peak: Controlled polymerization exotherm (< 62°C) minimizing thermal necrosis to cortical bone tissues.
- Packaging: 40g powder / 20ml liquid unit paired with optional vacuum mixing cartridges.
Revision Arthroplasty & Infection Control
3. Sharma-Fix G+ Antibiotic-Loaded PMMA Bone Cement (Gentamicin Impregnated)
Clinical Focus: Revision Arthroplasty, High-Risk Primary Joint Surgeries, and Periprosthetic Joint Infection (PJI) Prophylaxis.
Technical Profile: Formulated with pre-blended Gentamicin Sulfate (typically 1.0g to 2.0g active base per 40g powder dose). Sharma-Fix G+ releases therapeutic local concentrations of aminoglycoside antibiotics directly into the surgical bed, reaching localized Minimum Inhibitory Concentrations (MIC) far exceeding safe systemic intravenous levels.
- Elution Kinetics: High initial burst release over the first 48 hours followed by sustained bactericidal elution over 21 days.
- Spectrum: Effective against Staphylococcus aureus, Staphylococcus epidermidis, and major Gram-negative joint pathogens.
- Mechanical Retention: Homogeneous micronized antibiotic blending ensures zero sacrifice of compressive or flexural fatigue limits.
Spine & Minimally Invasive Surgery
4. Sharma-Fix VTP Radiopaque Vertebroplasty Cement
Clinical Focus: Percutaneous Vertebroplasty (PVP) and Kyphoplasty (PKP) for osteoporotic compression fractures.
Technical Profile: Formulated with ultra-high radio-contrast concentration (30% Zirconium Dioxide), enabling real-time visual tracking under continuous C-arm fluoroscopy. Maintains a consistent, smooth injection paste that prevents cement leakage into spinal canals or venous plexus vessels.
- Injection Window: Extended working time (up to 12 minutes at room temperature) for precise multi-level vertebral restoration.
- Particle Size: Micron-fine powder blend guaranteeing ultra-low extrusion resistance through 11G/13G bone biopsy needles.
Comprehensive Technical Specifications & ISO 5833 Benchmarks
To assist clinical evaluation teams and biomedical procurement agents in selecting the precise chemical formulation, the table below highlights the physical and mechanical parameters of Sharma Orthopedic Bone Cements under standardized testing conditions (23°C, 50% Relative Humidity):
| Parameters / Products | Sharma-Fix High Viscosity | Sharma-Fix Low Viscosity | Sharma-Fix G+ (Gentamicin) | Sharma-Fix VTP (Vertebroplasty) | ISO 5833 Requirement |
|---|---|---|---|---|---|
| Primary Surgical Application | Total Knee (TKR), Shoulder | Total Hip (THR) Injection | Revision Arthroplasty / PJI Risk | Spinal Kyphoplasty / PVP | N/A |
| Doughing Time (Min) | 1.0 – 1.5 min | 3.0 – 4.5 min | 1.2 – 2.0 min | 2.0 – 3.0 min | < 5.0 min |
| Working Time (Min) | 4.0 – 6.0 min | 6.0 – 9.0 min | 4.5 – 6.5 min | 10.0 – 14.0 min | Self-determined |
| Setting Time (Min) | 8.0 – 10.5 min | 11.0 – 14.0 min | 9.0 – 11.5 min | 14.0 – 18.0 min | 3.0 – 15.0 min |
| Compressive Strength (MPa) | 88.5 ± 3.2 MPa | 84.0 ± 2.8 MPa | 86.2 ± 3.5 MPa | 92.0 ± 4.1 MPa | ≥ 70.0 MPa |
| Flexural Modulus (MPa) | 2,950 ± 120 MPa | 2,810 ± 110 MPa | 2,900 ± 105 MPa | 3,100 ± 150 MPa | ≥ 1,800 MPa |
| Flexural Strength (MPa) | 62.4 ± 2.1 MPa | 58.9 ± 1.8 MPa | 60.8 ± 2.3 MPa | 65.1 ± 2.7 MPa | ≥ 50.0 MPa |
| Radiopacifier Agent | 10% ZrO2 / BaSO4 | 10% ZrO2 / BaSO4 | 10% Zirconium Dioxide | 30% Zirconium Dioxide | Required (Visible) |
| Sterilization Method | Ethylene Oxide / Gamma | Ethylene Oxide / Gamma | Aseptic Powder + ETO Liquid | Ethylene Oxide / Gamma | Validated Sterility Assurance (SAL 10⁻⁶) |
Note for Procurement Officers: Custom viscous handling windows, varied antibiotic dosing (e.g., Vancomycin, Tobramycin combinations), and private labeling options can be tailored upon bulk contract agreement. Contact our international regulatory affairs team for full technical file access (STED / CSDT documents).
Global Procurement & Market Trends in Orthopedic Bone Cement (2025–2030)
The global orthopedic bone cement market is undergoing structural shifts driven by demographic aging, rising joint replacement volumes across emerging economies, and heightened international regulatory scrutiny. B2B hospital buyers, ministry tenders, and medical importers must adapt their purchasing strategies to align with these emerging trends:
1. Transition to Closed Vacuum Mixing Systems
Manual bowl-and-spatula cement mixing is rapidly being phased out by surgical departments globally. Modern operating room safety guidelines emphasize closed vacuum mixing systems for two key reasons:
- Monomer Vapor Reduction: Protecting operating room staff from toxic Methyl Methacrylate (MMA) volatile fumes.
- Porosity Elimination: Vacuum mixing removes air bubbles, drastically reducing internal voids and increasing fatigue life under multi-axial cyclic loads by up to 300%.
Global suppliers capable of bundling bone cement units with single-use sterile vacuum mixing cartridges are securing preferential status in national hospital tenders.
2. Surging Demand for Antibiotic-Loaded Cements (ALBC)
With Periprosthetic Joint Infection (PJI) posing severe financial and clinical burdens on healthcare systems worldwide, ALBC has transitioned from being exclusively used in revision cases to serving as a routine prophylactic measure in primary hip and knee arthroplasty for high-risk cohorts (diabetic, immunocompromised, or elderly patients).
Distributors who maintain steady stock of pre-mixed Gentamicin and dual-antibiotic bone cements enjoy higher gross margins and recurring re-order rates from orthopedic hospitals.
3. Diversification Away from High-Cost Western OEM Brands
Hospital procurement boards across Latin America, Asia-Pacific, Eastern Europe, and Africa face severe cost-containment pressures. Premium Western bone cement brands often carry unsustainable price markups driven by inflated overheads.
Top-tier ISO 13485 manufacturers in India, such as Sharma Orthopedic, offer direct factory supply of CE-marked, ISO 5833 compliant PMMA cements at a fraction of the cost, empowering global buyers to maintain high clinical outcomes while optimizing surgical cost-per-case metrics.
4. Stringent EU MDR and Global Regulatory Compliance
The implementation of the European Union Medical Device Regulation (EU MDR 2017/745) has led to the exit of small-scale, unaccredited acrylic manufacturers due to rigorous clinical evaluation and post-market surveillance costs.
Importers must partner exclusively with manufacturers possessing robust Technical Master Files, ISO 10993 biocompatibility test data (cytotoxicity, systemic toxicity, sensitization), and long-term clinical registry backing.
Future Development Trends in Acrylic & Bioactive Bone Cements
As orthopedic surgical techniques evolve toward tissue-preserving, minimally invasive, and robot-assisted approaches, biomaterial science is pushing the boundaries of PMMA chemistry. Here are the core innovations shaping the next decade of orthopedic fixation:
Bioactive Osteo-conductive PMMA
Incorporating micronized Hydroxyapatite (HA) and beta-Tricalcium Phosphate (β-TCP) into PMMA matrices to induce direct bone apposition, eliminating the fibrotic capsule interface and reducing late aseptic loosening risks.
Nanostructure & Fiber Reinforcement
Integration of multi-walled carbon nanotubes (MWCNTs) and electrospun polymeric nanofibers to dramatically increase tensile strength and fracture toughness without impairing injectability or viscosity profiles.
Low-Exotherm Monomer Systems
Formulating novel co-monomers and thermal moderators that limit maximum polymerization temperatures to below 50°C, virtually eliminating thermal injury to surrounding bone tissue and cellular proteins.
30+
Years of Excellence
Enterprise Manufacturing Capabilities
Why Global Importers Partner with Sharma Orthopedic
Since 1992, Sharma Orthopedic India Limited has established itself as an elite orthopedic device manufacturer, blending European cleanroom standards with competitive Indian production logistics. Here is why distributors across 50+ nations rely on us:
Top 3
Implant & bone cement exporters in India
50+
Active international distribution markets
ISO
13485 & CE certified quality management
1992
30+ years of surgical manufacturing heritage
62Ksq.ft
State-of-the-art facility in Vadodara, Gujarat
Surgical Application Mapping
Bone Cement & Implant Synergy by Anatomical Region
From joint reconstruction to spinal stabilization—our PMMA cements are engineered to complement our complete orthopedic implant catalog.
Maxillofacial
Spine
Clavicle
Humerus
Radius / Ulna
Hand
Pelvic
Hip
Femur
Knee
Tibia / Fibula
Foot
Buyer's Intelligence
Orthopedic Bone Cement Procurement FAQ
Clear, authoritative answers to the most frequent technical, clinical, and regulatory questions submitted by international purchasing managers and hospital committees.
Q1: What is the primary functional difference between high-viscosity and low-viscosity bone cement, and how should surgical departments choose between them?
Answer: The distinction lies in the rheological progression of the dough state. High-viscosity cement reaches a non-sticky, doughy consistency almost immediately (within 60 to 90 seconds) and remains stable during manual packing. It is ideal for open surgical beds like Total Knee Replacement (TKR) tibial and femoral resurfacing, where the surgeon needs to knead and pressurize the cement by hand without it flowing away.
Conversely, low-viscosity cement remains liquid and fluid for several minutes post-mixing. This extended fluid phase allows easy loading into syringe injection guns and vacuum delivery devices, permitting deep, pressurized insertion into retro-grade femoral canals during Total Hip Replacement (THR). The choice depends entirely on the surgical technique, cement gun availability, and joint pathology.
Q2: How does antibiotic-loaded PMMA bone cement mitigate the risk of Periprosthetic Joint Infection (PJI)?
Answer: Antibiotic-loaded bone cement (ALBC) acts as a local drug delivery system. Systemic intravenous antibiotics often struggle to reach therapeutic levels in bone tissue with compromised vascularization around an implant bed. By embedding heat-stable antibiotics (such as Gentamicin Sulfate or Tobramycin) directly into the PMMA powder matrix, high local concentrations of the antibacterial agent elute into the immediate peri-implant fluid hematoma over the critical initial 48 to 72 hours post-surgery.
This localized concentration is up to 100 times higher than levels achievable through IV administration alone—effectively killing planktonic bacteria and preventing biofilm formation on the implant surface without causing systemic renal toxicity.
Q3: What regulatory documentation and standards (ISO 5833, ISO 13485) are required to import bone cement?
Answer: Bone cement is classified as a high-risk Class III medical device (under US FDA and EU MDR frameworks) because it remains permanently implanted in human skeletal tissue. Importers must verify that the manufacturing site operates under ISO 13485 (Medical Devices - Quality Management Systems) certification.
Furthermore, the cement formulation must strictly comply with ISO 5833 (Implants for surgery — Acrylic resin cements), which dictates rigorous physical testing: compressive strength (≥70 MPa), flexural modulus (≥1800 MPa), setting time (3 to 15 mins), and maximum exothermic peak temperature (≤90°C). Full ISO 10993 biocompatibility reports (cytotoxicity, systemic toxicity, sensitization, and pyrogenicity) must also accompany the product dossier.
Q4: How does vacuum mixing impact the structural integrity and longevity of PMMA bone cement?
Answer: Hand-mixing bone cement in open bowls introduces atmospheric air micro-bubbles into the polymerizing matrix. These air voids act as mechanical stress concentrators when subjected to dynamic physiological loads, leading to premature fatigue cracking and cement mantle fragmentation.
Utilizing a closed vacuum mixing system (operating at approximately -200 to -800 mbar) evacuates trapped air and monomer gases. Vacuum-mixed cement exhibits up to 80% lower volumetric porosity, resulting in enhanced fatigue resistance, higher flexural strength, and significantly longer mantle survival rates in clinical follow-ups.
Q5: What is the typical shelf life, storage environment, and sterilization protocol for Sharma-Fix bone cement kits?
Answer: Sharma-Fix bone cement kits have a validated shelf life of 3 to 5 years from the date of manufacture. Storage must be maintained below 25°C in a dry, dark location to prevent premature thermal polymer cross-linking of the liquid monomer (MMA).
Each kit contains two distinct components sterilized via validated methods:
- Powder Component (PMMA polymer + radiopacifier + initiator): Sterilized using Ethylene Oxide (ETO) gas or Gamma Irradiation.
- Liquid Component (MMA monomer + accelerator + hydroquinone stabilizer): Aseptically filtered and sealed in glass ampoules, protected against light degradation.
Q6: Can Sharma Orthopedic accommodate custom OEM/ODM packaging, custom viscosity profiles, or regional tender branding?
Answer: Yes. As an integrated manufacturer with an extensive 62,391 sq. ft facility in Vadodara, Gujarat, Sharma Orthopedic provides full OEM/ODM contract manufacturing services for international distributors and pharmaceutical brands. We offer customized packaging sizes (e.g., 20g, 40g, 60g doses), tailored radiopacifier ratios (Zirconium Dioxide vs. Barium Sulfate), private label branding, and complete technical dossier assembly (CSDT format) for fast-track local ministry registrations.
Company Overview
Sharma Orthopedic — 30+ Years of Surgical Excellence
Established in 1992, Sharma Orthopedic India Limited has grown from a specialized enterprise into a globally recognized manufacturer and exporter of precision orthopedic implants, acrylic bone cements, and surgical instruments.
- Headquartered in Waghodia, Gujarat — 62,391 sq. ft. state-of-the-art facility
- Full product range: Arthroplasty (THR/TKR), PMMA Cements, Osteosynthesis, Spinal & Arthroscopy
- Advanced 5-axis CNC machining, cleanroom chemical processing & in-house R&D
- Exported to 50+ countries across Asia, Africa, Latin America, Europe & the Americas
- ISO 13485 certified quality management — CE marked product dossiers
45
Sales Team
8
RA / QA Experts
100
Production Staff
10
QC Department
40
Administration
5
R&D / Design
Ready to Source Premium Orthopedic Bone Cement?
Connect directly with our international export department for official catalogs, technical specifications, and factory-direct quotation sheets.
[email protected]
Global Export Enquiries
Get Catalog